HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increase in short-term risk of rejection in heart transplant patients receiving granulocyte colony-stimulating factor.

AbstractBACKGROUND:
Neutropenia is a significant adverse event after heart transplantation (HT) and increases infection risk. Granulocyte colony-stimulating factor (G-CSF) is commonly used in patients with neutropenia. In this work, we assessed the adverse effects of G-CSF treatment in the setting of a university hospital.
METHODS:
Data on HT patients from January 2008 to July 2016 were reviewed. Patients who received G-CSF were identified and compared with patients without a history of therapy. Baseline characteristics, rejection episodes, and outcomes were collected. Data were analyzed by incidence rates, time to rejection and survival were analyzed using Kaplan-Meier curves, and odds ratios were generated using logistic regression analysis.
RESULTS:
Two hundred twenty-two HT patients were studied and 40 (18%) received G-CSF for a total of 85 total neutropenic events (0.79 event/patient year). There were no differences in baseline characteristics between the groups. In the 3 months after G-CSF, the incidence rate of rejection was 0.067 event/month. In all other time periods considered free of G-CSF effect, the incidence rate was 0.011 event/month. This rate was similar to the overall incidence rate in the non-GCSF group, which was 0.010 event/month. There was a significant difference between the incidence rates in the G-CSF group at 0 to 3 months after G-CSF administration and the non-GCSF group (p = 0.04), but not for the other time periods (p = 0.5). Freedom from rejection in the 3 months after G-CSF administration was 87.5% compared with 97.5% in the non-GCSF group (p = 0.006).
CONCLUSIONS:
G-CSF administration was found to be associated with significant short-term risk of rejection. This suggests the need for increased surveillance during this time period.
AuthorsAnn B Nguyen, Laura Lourenço, Ben Bow Chung, Teruhiko Imamura, Daniel Rodgers, Stephanie A Besser, Catherine Murks, Tiana Riley, JoDel Powers, Jayant Raikhelkar, Sara Kalantari, Nitasha Sarswat, Valluvan Jeevanandam, Gene Kim, Gabriel Sayer, Nir Uriel
JournalThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (J Heart Lung Transplant) Vol. 37 Issue 11 Pg. 1322-1328 (11 2018) ISSN: 1557-3117 [Electronic] United States
PMID30174163 (Publication Type: Journal Article)
CopyrightCopyright © 2018 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Granulocyte Colony-Stimulating Factor
Topics
  • Female
  • Graft Rejection (chemically induced)
  • Granulocyte Colony-Stimulating Factor (adverse effects, therapeutic use)
  • Heart Transplantation
  • Hospitals, University
  • Humans
  • Male
  • Middle Aged
  • Neutropenia (drug therapy)
  • Risk

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: